Senseonics Announces $80 Million Public Offering
Senseonics Holdings, Inc. has launched an underwritten public offering of $80 million, which includes common stocks and pre-funded warrants to certain investors. The company plans to use the proceeds for the launch of Eversense 365 and the development of other products, along with working capital. The offering is subject to market conditions, and the final terms will be outlined in a prospectus supplement to be filed with the SEC.
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) — Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock and, to certain investors, pre-funded warrants to purchase its common stock in lieu thereof. In connection with the proposed offering, Senseonics also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares offered in the public offering. All of the securities to be sold in the proposed offering will be offered by Senseonics. The pre-funded warrants will not be listed on any securities exchange.